Relafen 750, also known as naproxen, represents a fascinating case study in biochemical pharmacy. This mechanism of action requires the inhibition of cyclooxygenase proteins, specifically COX-1 and COX-2, thereby alleviating prostaglandin synthesis . Examining the nuanced interplay within Relafen 750 and these enzymatic pathways provides valuable i